secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2021-09-28T23:59:59+00:00
Accession:  0001193125-21-284964
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector appoints Elizabeth Garofalo, M.D. to Board of Directors
---------------------------------------------------------------

- Dr. Garofalo appointed as Class II director with term expiring at 2023 annual meeting; effective Sept. 23, 2021.
- Over 25 years of neurology drug development experience; formerly SVP and Global Head of Clinical Development at Novartis.
- Received initial option grant of 33,235 shares (four-year vest) and annual cash retainer of $40,000.
- Currently serves on boards of Acadia Pharmaceuticals, Exicure Inc., and Xenon Pharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000119312521284964/0001193125-21-284964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000119312521284964/d234235d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-284964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer